No results for ‘’
Poly Medicure Ltd
₹1563.30
(0.63%)
Wed, 24 Jun 2026, 11:58 pm
Health Technology
Medical Specialties
24.5KPoly Medicure EV/EBITDA Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 6.64 | 8.32 | 6.34 | 3.88 | 6.81 | 14.16 | 14.34 | 20.48 | 22.12 | 35.43 | 25.70 | 43.55 | 31.26 | 29.29 | 21.69 | 53.65 | 62.15 | 51.05 | 59.07 | 65.72 |
| Price to book ratio | 1.71 | 1.96 | 1.09 | 0.48 | 1.76 | 3.92 | 2.99 | 4.41 | 6.81 | 11.26 | 5.43 | 8.84 | 6.52 | 5.02 | 4.78 | 8.12 | 8.37 | 7.36 | 10.37 | 8.21 |
| Price to sales ratio | 0.68 | 0.81 | 0.54 | 0.21 | 0.79 | 1.82 | 1.33 | 1.95 | 3.17 | 5.75 | 3.04 | 5.36 | 4.34 | 3.22 | 3.10 | 9.36 | 9.91 | 8.24 | 11.15 | 13.43 |
| Price to cash flow ratio | 4.21 | 7.60 | 7.85 | 2.58 | 6.27 | 16.04 | 10.63 | 15.06 | 17.16 | 39.44 | 21.76 | 46.73 | 32.68 | 19.67 | 16.54 | 64.18 | 73.69 | 49.54 | 56.76 | 91.10 |
| Enterprise value | 61.79Cr | 94.67Cr | 83.34Cr | 58.93Cr | 139Cr | 346Cr | 325Cr | 544Cr | 1050Cr | 2266Cr | 1301Cr | 2478Cr | 2308Cr | 2021Cr | 2245Cr | 7052Cr | 8880Cr | 8999Cr | 15144Cr | 21224Cr |
| Enterprise value to EBITDA ratio | 4.66 | 5.74 | 7.32 | 2.18 | 4.53 | 10 | 6.40 | 8.62 | 14.47 | 28.43 | 14.83 | 27.95 | 20.51 | 17.26 | 14.62 | 33.19 | 41.28 | 33.15 | 41.99 | 47.05 |
| Debt to equity ratio | 0.53 | 0.76 | 0.85 | 0.76 | 0.54 | 0.52 | 0.49 | 0.43 | 0.46 | 0.40 | 0.36 | 0.37 | 0.39 | 0.42 | 0.48 | 0.14 | 0.12 | 0.12 | 0.12 | 0.07 |
| Return on equity % | 0 | 26.32 | 19.58 | 13.24 | 29.14 | 31.29 | 22.72 | 23.57 | 34.87 | 36.40 | 22.73 | 22.04 | 23.15 | 18.17 | 23.49 | 19.40 | 14.27 | 15.39 | 19.05 | 15.99 |
Poly Medicure Ltd Enterprise Value to EBITDA Ratio
The Poly Medicure Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Poly Medicure Ltd's valuation, profitability, and overall financial performance. Tracking the Poly Medicure Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Poly Medicure Ltd (NSE: POLYMED, BSE: 531768) is currently trading at ₹1563.30, with a market capitalization of ₹15837.93Cr. As a leading company in the Health technology sector and Medical specialties industry, monitoring the Poly Medicure Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.
Poly Medicure Ltd Enterprise Value to EBITDA Ratio Current Value
The current Poly Medicure Ltd Enterprise Value to EBITDA Ratio stands at 47.05.
The latest Poly Medicure Ltd Enterprise Value to EBITDA Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Poly Medicure Ltd Enterprise Value to EBITDA Ratio Historical Trend
The Poly Medicure Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:
- 2024: 47.05
- 2023: 41.99
- 2022: 33.15
- 2021: 41.28
- 2020: 33.19
The recent rise in Poly Medicure Ltd Enterprise Value to EBITDA Ratio suggests strengthening valuation trends and improving market sentiment.
What Poly Medicure Ltd Enterprise Value to EBITDA Ratio Indicates for Investors
The Poly Medicure Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Poly Medicure Ltd.
Poly Medicure Ltd Enterprise Value to EBITDA Ratio Analysis Summary
The Poly Medicure Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Poly Medicure Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Poly Medicure Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.